IVAX CORP /DE
S-3, EX-12, 2000-08-07
PHARMACEUTICAL PREPARATIONS
Previous: IVAX CORP /DE, S-3, EX-5, 2000-08-07
Next: IVAX CORP /DE, S-3, EX-23.1, 2000-08-07




EXHIBIT 12
Computation of Ratio of Earnings to Fixed Charges
(dollars in thousands)
(unaudited)
<TABLE>
<CAPTION>
                                                                                                                     3 Months Ended
                                                        Years Ended December 31,                                        March 31,
                                          -----------------------------------------------------------------------------------------
                                               1995           1996           1997           1998           1999           2000
<S>                                       <C>             <C>              <C>              <C>            <C>            <C>
Fixed Charges
    Interest expense on indebtedness      $    8,086      $    15,996      $    14,685      $   6,857      $   5,556      $   2,042
    Interest expense on portion of rent
    expense representative of interest           498              435              394            340            366             96

    Total Fixed Charges                        8,584      $    16,431      $    15,079      $   7,197      $   5,922      $   2,138

Earnings (Loss):
    Net income (loss) before provision for
    income taxes and minority interest    $  124,128      $  (189,389)     $  (160,544)     $  34,876      $  84,735      $  30,249

    Fixed charges per above                    8,584           16,431           15,079          7,197          5,922          2,138

    Total earnings (loss)                 $  132,712      $  (172,958)     $  (145,465)     $  42,073      $  90,657      $  32,387

Ratio of earnings to fixed charges             15.46           (10.53)           (9.65)         (5.85)         15.31          15.15

Coverage deficiency                             -         $  (189,389)     $  (160,544)     $    -              -              -
</TABLE>



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission